提示: 手机请竖屏浏览!

Vitamin D Supplementation and Prevention of Type 2 Diabetes

Anastassios G. Pittas ... 糖尿病 • 2019.08.08
• 补充维生素D未能预防2型糖尿病 • 补充维生素D是否能够预防2型糖尿病? • 补充维生素D——VITAL研究的结果






我们将符合糖尿病前期3项血糖标准(空腹血糖水平,100~125 mg/dL;75 g口服葡萄糖负荷后2小时的血糖水平,140~199 mg/dL;糖化血红蛋白水平,5.7%~6.4%)中的至少2项,并且不符合糖尿病诊断标准的成人随机分组,分别每日接受4,000 IU维生素D3或安慰剂,而不考虑基线血清25-羟基维生素D水平。在此项至事件发生时间分析中,主要结局是新发糖尿病,我们将试验设计为事件驱动,糖尿病事件的目标数量为508。



共有2,423名参与者接受了随机分组(维生素D组1,211名,安慰剂组1,212名)。截至第24个月,维生素D组的平均血清25-羟基维生素D水平为54.3 ng/mL(基线时为27.7 ng/mL),而安慰剂组为28.8 ng/mL(基线时为28.2 ng/mL)。经过中位2.5年随访,维生素D组293名参与者和安慰剂组323名参与者发生了糖尿病这一主要结局(分别为每100人-年9.39起事件和10.66起事件)。维生素D与安慰剂相比的风险比为0.88(95%置信区间[CI],0.75~1.04;P=0.12)。两组的不良事件发生率无显著差异。



在未针对维生素D缺乏情况进行选择的2型糖尿病高危人群中,每日补充4,000 IU维生素D3与安慰剂相比未显著降低糖尿病风险(由美国国立糖尿病、消化和肾脏病研究所[National Institute of Diabetes and Digestive and Kidney Diseases]等资助;D2d在ClinicalTrials.org注册号为NCT01942694)。


Anastassios G. Pittas, M.D., Bess Dawson-Hughes, M.D., Patricia Sheehan, R.N., M.P.H., M.S., James H. Ware, Ph.D., William C. Knowler, M.D., Dr.P.H., Vanita R. Aroda, M.D., Irwin Brodsky, M.D., Lisa Ceglia, M.D., Chhavi Chadha, M.D., Ranee Chatterjee, M.D., M.P.H., Cyrus Desouza, M.B., B.S., Rowena Dolor, M.D., John Foreyt, Ph.D., Paul Fuss, B.A., Adline Ghazi, M.D., Daniel S. Hsia, M.D., Karen C. Johnson, M.D., M.P.H., Sangeeta R. Kashyap, M.D., Sun Kim, M.D., Erin S. LeBlanc, M.D., M.P.H., Michael R. Lewis, M.D., Emilia Liao, M.D., Lisa M. Neff, M.D., Jason Nelson, M.P.H., Patrick O’Neil, Ph.D., Jean Park, M.D., Anne Peters, M.D., Lawrence S. Phillips, M.D., Richard Pratley, M.D., Philip Raskin, M.D., Neda Rasouli, M.D., David Robbins, M.D., Clifford Rosen, M.D., Ellen M. Vickery, M.S., and Myrlene Staten, M.D. for the D2d Research Group*
From Tufts Medical Center (A.G.P., L.C., P.F., J.N., E.M.V.), the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (B.D.-H.), Brigham and Women’s Hospital (V.R.A.), and Harvard School of Public Health (J.H.W.), Boston, and the Spaulding Rehabilitation Network, Charlestown (P.S.) — all in Massachusetts; National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ (W.C.K.); the Maine Medical Center (I.B.) and the Maine Medical Center Research Institute (C.R.) — both in Scarborough; HealthPartners Institute, Minneapolis (C.C.); Duke University Medical Center, Durham, NC (R.C., R.D.); the University of Nebraska Medical Center and Omaha Veterans Affairs Medical Center, Omaha (C.D.); Baylor College of Medicine, Houston (J.F.), and the University of Texas Southwestern Medical Center, Dallas (P.R.) — both in Texas; MedStar Good Samaritan Hospital, Baltimore (A.G.), MedStar Health Research Institute, Hyattsville (J.P.), and the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (M.S.) — all in Maryland; Pennington Biomedical Research Center, Baton Rouge, LA (D.S.H.); the University of Tennessee Health Science Center, Memphis (K.C.J.); Cleveland Clinic, Cleveland (S.R.K.); Stanford University Medical Center, Stanford (S.K.), and the Keck School of Medicine of the University of Southern California, Los Angeles (A.P.) — both in California; Kaiser Permanente Center for Health Research–Northwest, Portland, OR (E.S.L.); the University of Vermont, Burlington (M.R.L.); Northwell Health Lenox Hill Hospital, New York (E.L.); Northwestern University, Chicago (L.M.N.); the Medical University of South Carolina, Charleston (P.O.); Emory University School of Medicine, Atlanta, and the Atlanta Veterans Affairs Medical Center, Decatur — both in Georgia (L.S.P.); AdventHealth Translational Research Institute for Metabolism and Diabetes, Orlando, FL (R.P.); the University of Colorado Denver and the Veterans Affairs Eastern Colorado Health Care System, Denver (N.R.); and the University of Kansas Medical Center, Kansas City (D.R.). Address reprint requests to Dr. Pittas at the Division of Endocrinology, Diabetes, and Metabolism, Tufts Medical Center, 800 Washington St., Box 268, Boston, MA 02111, or at apittas@tuftsmedicalcenter.org. James H. Ware, Ph.D., is deceased. *A list of the members of the D2d Research Group is provided in the Supplementary Appendix, available at NEJM.org.



1. Centers for Disease Control and Prevention. National diabetes statistics report, 2017 (https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdfopens in new tab).

2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.

3. Lu L, Bennett DA, Millwood IY, et al. Association of vitamin D with risk of type 2 diabetes: a Mendelian randomisation study in European and Chinese adults. PLoS Med 2018;15(5):e1002566-e1002566.

4. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92:2017-2029.

5. Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010;33:1379-1381.

6. Song Y, Wang L, Pittas AG, et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care 2013;36:1422-1428.

7. Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr 2011;94:486-494.

8. Seida JC, Mitri J, Colmers IN, et al. Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:3551-3560.

9. Mirhosseini N, Vatanparast H, Mazidi M, Kimball SM. Vitamin D supplementation, glycemic control, and insulin resistance in prediabetics: a meta-analysis. J Endocr Soc 2018;2:687-709.

10. Tang H, Li D, Li Y, Zhang X, Song Y, Li X. Effects of vitamin D supplementation on glucose and insulin homeostasis and incident diabetes among nondiabetic adults: a meta-analysis of randomized controlled trials. Int J Endocrinol 2018;2018:7908764-7908764.

11. Pittas AG, Dawson-Hughes B, Sheehan PR, et al. Rationale and design of the Vitamin D and Type 2 Diabetes (D2d) study: a diabetes prevention trial. Diabetes Care 2014;37:3227-3234.

12. American Diabetes Association. Standards of medical care in diabetes — 2010. Diabetes Care 2010;33:Suppl 1:S11-S61.

13. Aroda VR, Sheehan PR, Vickery EM, et al. Establishing an electronic health record-supported approach for outreach to and recruitment of persons at high risk of type 2 diabetes in clinical trials: the Vitamin D and Type 2 diabetes (D2d) study experience. Clin Trials 2019;16:308-315.

14. Gökçe C, Gökçe O, Baydinç C, et al. Use of random urine samples to estimate total urinary calcium and phosphate excretion. Arch Intern Med 1991;151:1587-1588.

15. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-2081.

16. Forrest RD, Jackson CA, Yudkin JS. The glycohaemoglobin assay as a screening test for diabetes mellitus: the Islington Diabetes Survey. Diabet Med 1987;4:254-259.

17. Bedner M, Lippa KA, Tai SS. An assessment of 25-hydroxyvitamin D measurements in comparability studies conducted by the Vitamin D Metabolites Quality Assurance Program. Clin Chim Acta 2013;426:6-11.

18. DEQAS (Vitamin D External Quality Assessment Scheme) (http://www.deqas.orgopens in new tab).

19. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics 1983;39:499-503.

20. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793-797.

21. Lachin JM. Maximum information designs. Clin Trials 2005;2:453-464.

22. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34:187-220.

23. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press, 2011.

24. LeBlanc ES, Pratley RE, Dawson-Hughes B, et al. Baseline characteristics of the Vitamin D and Type 2 Diabetes (D2d) study: a contemporary prediabetes cohort that will inform diabetes prevention efforts. Diabetes Care 2018;41:1590-1599.

25. Jorde R, Sollid ST, Svartberg J, et al. Vitamin D 20,000 IU per week for five years does not prevent progression from prediabetes to diabetes. J Clin Endocrinol Metab 2016;101:1647-1655.

26. Kawahara T, Suzuki G, Inazu T, et al. Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study. BMJ Open 2016;6(7):e011183-e011183.

27. Kawahara T. Eldecalcitol, a vitamin D analog, for diabetes prevention in impaired glucose tolerance (DPVD study). Diabetes 2018;67:Suppl 1 (poster) (http://diabetes.diabetesjournals.org/content/67/Supplement_1/120-LBopens in new tab).

28. Grant WB, Boucher BJ, Bhattoa HP, Lahore H. Why vitamin D clinical trials should be based on 25-hydroxyvitamin D concentrations. J Steroid Biochem Mol Biol 2018;177:266-269.

29. Rooney MR, Harnack L, Michos ED, Ogilvie RP, Sempos CT, Lutsey PL. Trends in use of high-dose vitamin D supplements exceeding 1000 or 4000 international units daily, 1999-2014. JAMA 2017;317:2448-2450.

30. National Institutes of Health. Vitamin D: fact sheet for health professionals (https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/opens in new tab).

31. Jones AN, Shafer MM, Keuler NS, Crone EM, Hansen KE. Fasting and postprandial spot urine calcium-to-creatinine ratios do not detect hypercalciuria. Osteoporos Int 2012;23:553-562.

服务条款 | 隐私政策 | 联系我们